We are live on ! Find out more
GBIO

Generation Bio

Delisted

GBIO was delisted on the 6th of February, 2026.

77 hedge funds and large institutions have $156M invested in Generation Bio in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

25% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 24

4% more funds holding

Funds holding: 7477 (+3)

0.07% more ownership

Funds ownership: 8.27%8.34% (+0.07%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

30% less capital invested

Capital invested by funds: $224M → $156M (-$67.2M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
77
Holders Change
+3
Holders Change %
+4.05%
% of All Funds
1.11%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
12
Increased
30
Reduced
24
Closed
9
Calls
Puts
$1K
Net Calls
-$1K
Net Calls Change
-$84K

GBIO Hedge Fund Activity: Q2 2024 in Review

77 of the 6,928 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q2 2024, worth a combined $156M — down 30% from $224M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new GBIO positions and 9 closed out — a net gain of 3 holders — while 30 added to existing stakes and 24 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $2.72M. The largest seller was PFM Health Sciences, cutting an estimated $2.71M.

  • 77 institutional investors held Generation Bio (GBIO) as of Q2 2024, up from 74 in Q1 2024.
  • Funds reported $156M of Generation Bio stock for Q2 2024, down 30% quarter-over-quarter.
  • 12 funds opened new Generation Bio positions in Q2 2024 and 9 closed out, a net change of +3 holders.
  • The largest Generation Bio buyer in Q2 2024 was Baker Bros. Advisors, an estimated $2.72M added.
  • The largest Generation Bio seller in Q2 2024 was PFM Health Sciences, an estimated $2.71M sold.

Based on aggregated 13F filings for Q2 2024.